ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AMRN / news
ABEO (23) CAMP (26) IFRX (54) GLSI (31) ⌘ Pro Terminal →

Why AMRN Stock advanced +0.17% Today — RQD Quant Desk Flash

$12.13 +0.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.11

Amarin Corporation plc (AMRN) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $249.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMRN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Amarin Corporation plc (NASDAQ: AMRN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $12.13 (+0.17% 1D, market cap $249.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, AMRN ranks #716 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMRN compare to ABEO and CAMP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -12.2%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $248.8M) and CAMP (CAMP4 Therapeutics Corporation) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $248.5M). Among the 5-stock peer group, AMRN leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMRN?
▼

Per AMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000897448), Amarin Corporation plc generated $213.6M in revenue (-6.5% YoY), -$38.8M in net income, and $6.7M in free cash flow against $670.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.11 (-0.16%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (8)Whales (5)SEC (6)Macro (6)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$18 Bull$11 Base$8 Bear
📬 FREE AMRN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMRN)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY AMRN SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 3.1% FCF Margin ($6.7M FCF) & 56.6% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Disciplined Float (+0.16% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
24
Grade E$11.58-0.9% Next Q
Q2 (-2Q)
27
Grade E$11.48+4.1% Next Q
Q3 (-1Q)
29
Grade E$11.95+1.5% Next Q
Current
32
Grade E$12.13-9.2% Hist 90D α
Trajectory: E (24) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AMRN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AMRN currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.91) and Max Pain ($12.74) forces dealer call-delta covering toward $18.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMRN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why AMRN Stock advanced +0.17% Today — RQD Quant Desk Flash

Amarin Corporation plc (AMRN) advanced +0.17% to $12.13, trading at 15% of its 52-week range ($11.25 – $17.31). Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 15% of its 52-week range ($11.25 – $17.31) with RSI-14 at 47.1 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±7.2% around $12.13 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 56.6% gross margin and $6.7M annual free cash flow.
Live AMRN Headlines & Catalysts
RISK WATCHYahoo • 5d ago
Amarin (AMRN) Q3 Results Recast Profit Story As Revenue Falls

Amarin just turned in Q3 2026 results that flipped a long running story. After a year of losses, the biotech posted a small profit of US$0.245 million and delivered its fourth straight quarter of positive operating cash

RISK WATCHYahoo • 6d ago
Amarin: Q3 Earnings Snapshot

DUBLIN (AP) — DUBLIN (AP) — Amarin Corp. PLC (AMRN) on Wednesday reported third-quarter net income of $245,000, after reporting a loss in the same period a year earlier.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMRN)

  • ✓Walkthrough of AMRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AMRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.82%▼ DESCENDING CHANNEL
2026-11-03O $12.73H $12.73L $12.11C $12.13VOL 101.3K
RES: $13.04SUP: $10.80SMA50: $12.91SMA200: $14.29
$17.67$15.93$14.19$12.45$10.71RES $13.04SUP $10.80$12.132026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMRN Butterfly Map → + Track AMRN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -6.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMRN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMRN)

Health Care Rank #716 of 1015 ⚔️ ABEO vs AMRN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMRN vs. ABEO, CAMP, IFRX, GLSI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Amarin Corporation plc (AMRN) ranks #716 by composite RQD confidence (32/100, grade E) and #540 by equity capitalization ($249.9M). Within this direct 5-issuer industry benchmark cohort, AMRN leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. IFRX currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with AMRN at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMRN ACTIVE
Amarin Corporation plc
E 32/100 — 56.6% -12.2% +0.17% $249.9M Benchmark Subject
ABEO
Abeona Therapeutics Inc.
E 23/100 — 73.7% -35.0% -2.30% $248.8M /abeo-vs-amrn →
CAMP
CAMP4 Therapeutics Corporation
E 26/100 — — -35.0% -4.67% $248.5M /camp-vs-amrn →
IFRX
InflaRx N.V.
D+ 54/100 — — — +6.33% $244.6M /ifrx-vs-amrn →
GLSI
Greenwich LifeSciences Inc.
E 31/100 — — -35.0% -5.46% $255.5M /glsi-vs-amrn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000897448 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amarin Corporation plc (AMRN) reported GAAP revenue of $213.6M (-6.5% vs. FY2024 revenue of $228.6M , and -30.4% cumulative change since FY2023) , GAAP net income of -$38.8M, operating cash flow of $6.7M, and free cash flow of $6.7M (+121.7% YoY). On the balance sheet, AMRN closed FY2025 with $670.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $213.6M -$38.8M $6.7M $6.7M $670.8M —
FY2024 (FY) 2024-12-31 $228.6M -$87.0M -$31.0M -$31.0M $685.3M —
FY2023 (FY) 2023-12-31 $306.9M -$55.0M $6.9M $6.9M — —

3. AMRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Amarin Corporation plc (NASDAQ: AMRN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $12.13 (+0.17% 1D, market cap $249.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, AMRN ranks #716 in composite RQD confidence.

How does AMRN compare to ABEO and CAMP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -12.2%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $248.8M) and CAMP (CAMP4 Therapeutics Corporation) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $248.5M). Among the 5-stock peer group, AMRN leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMRN?

Per AMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000897448), Amarin Corporation plc generated $213.6M in revenue (-6.5% YoY), -$38.8M in net income, and $6.7M in free cash flow against $670.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMRN trading relative to its 50-day, 200-day, and 52-week technical levels?

AMRN last traded at $12.13 (+0.17% on volume of 100,144 shares), positioning the stock -6.04% below its 50-day simple moving average ($12.91) and -15.12% below its 200-day simple moving average ($14.29). Across its 52-week range of $11.25 to $17.31, AMRN sits at the 14.5% percentile with a 14-day RSI of 47.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($11.26 to $13.00).

Direct Sub-Reports: AMRN RQD Cockpit AMRN 12M Forecast AMRN Earnings & Move AMRN Dividends & DRIP AMRN Insiders & 13F AMRN Whale Options AMRN Profit Sankey AMRN News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

AMRN — Amarin Corporation plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Amarin Corporation plc (AMRN) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $12.13 (+0.17% 1D, market capitalization $249.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -12.2%, gross margin of 56.6%, operating margin of -23.5%, and free cash flow yield of 2.56%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Amarin Corporation plc is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amarin Corporation plc (AMRN) reported $213.6M in annual revenue (up from $228.6M in FY2024, -6.5% YoY) and -$38.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($306.9M revenue, -$55.0M net income) through FY2025, AMRN scaled operating cash flow to $6.7M and free cash flow to $6.7M, backed by $670.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 2.56% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $11.25 – $17.31 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -23.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), AMRN carries a macro regime beta of 1.00 and gross margin of 56.6%.

  • Key Question #1: Can AMRN sustain or expand its -23.5% operating margin and -12.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $213.6M and free cash flow of $6.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AMRN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AMRN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amarin Corporation plc (AMRN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMRN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMRN Bull vs. Bear Conversation Board — What's Your Call at $12.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMRN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AMRN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $15.02 (+24.0%)
📌 Pinned Debate

Per the news feed, Amarin reportedly returned to quarterly profit as cost reductions offset a 20% revenue decline, with Q3 earnings bea

Here is why I am bullish on AMRN here at $12.11: Per the news feed, Amarin reportedly returned to quarterly profit as cost reductions offset a 20% revenue decline, with Q3 earnings beating estimates.. Compare AMRN's -23.5% operating margin and -12.2% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $11.50 are getting bought.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (56.6%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $9.81 (-19.0%)
Spot @ $12.11

Per the Roarable RQD rating, an Altman Z-Score of 0.2 and ROIC of -12.2% signal balance-sheet fragility and negative returns on capital

Careful chasing AMRN at $12.11. Per the Roarable RQD rating, an Altman Z-Score of 0.2 and ROIC of -12.2% signal balance-sheet fragility and negative returns on capital.. Gross margin is 56.6%, but operating margin is -23.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $9.81 on multiple compression.

LIVE TAPE